Company intelligence / Profile preview

Trianta Immunotherapies

Munich, Germany

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Trianta's dendritic cell vaccines were being evaluated in two ongoing investigator-initiated trials: a Phase I/II trial in acute myeloid leukemia at Ludwig-Maximilians University Hospital Großhadern, Munich, and a Phase II trial in prostate cancer at Oslo University Hospital. Previous clinical compassionate use studies provided encouraging data for safety and clinical benefits in several tumor types.

Therapeutic areas: HematologyImmunologyOncology
Modalities: Dendritic cell therapyT cell receptor engineered T cell therapyMonoclonal antibody
Industry: Biotech

Partnerships

Helmholtz Zentrum MünchenMax Delbrück Centre for Molecular Medicine BerlinLudwig-Maximilians University Hospital GroßhadernOslo University Hospital

Beyond the preview

Go deeper on Trianta Immunotherapies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trianta Immunotherapies.

Explore the full profile